Reports Q3 revenue $4.24M, consensus $3.3M. "We are excited with the progress we continue to make across all our clinical and pre-clinical programs. We have now seen evidence of monotherapy clinical activity with MT-6402, MT-5111, and MT-0169 in heavily pretreated relapsed/refractory patients — in both solid and hematological cancer settings — demonstrating the broad potential utility of this novel scaffold," said Eric Poma, Chief Executive and Chief Scientific Officer of Molecular Templates. "We look forward to providing further updates on our MT-6402, MT-5111, and MT-0169 programs throughout 2023 and look forward to our anticipated IND submission for MT-8421 all while we continue to advance our development of additional ETB candidates targeting TROP2, TIGIT, and BCMA."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MTEM: